Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PharmaTher Holdings Ltd.

PharmaTher Receives US FDA Approval Goal Date for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Provides Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher CEO Issues Letter to Shareholders
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM CSE:PHRX LMLLF PHRRF
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM CSE:PHRX LMLLF PHRRF
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM CSE:PHRX LMLLF PHRRF
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM CSE:PHRX LMLLF PHRRF
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM CSE:PHRX LMLLF PHRRF
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Provides Update for Expected FDA Approval of Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Holdings Provides Corporate Update
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Tickers CSE:PHRM PHRRF
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback